TX-COGNITE
17.1.2023 08:01:50 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced B. Braun, a leading medical technology company, has selected Cognite Data Fusion® as the core of its Manufacturing Data Management solution. By integrating Cognite’s Industrial DataOps platform with its manufacturing domain knowledge, B. Braun leverages digital twins and AI-powered applications to achieve operational excellence across production, maintenance, and sustainability.
The Manufacturing Data Management solution will provide a fully digital DevOps workflow to develop, deploy, and sustain a pipeline of business applications. Cognite Data Fusion® will integrate and contextualize all operational data from product development, engineering, production, quality management, maintenance, EHS, and enterprise systems into one contextualized data layer that adheres to and extends industry standards for data modeling and enables the evolution of those data models over time as needed. The Manufacturing Data Management solution will provide comprehensive, easily accessible, and trusted information to both domain experts and developers, creating the foundation for data-driven transformation at scale.
Abram Ziegelaar, VP of Operational Technology at B. Braun Medical Industries in Malaysia, highlights three main value drivers of the solution:
"First, our wide variety of front-line workers and domain experts can collaborate with a common pool of trusted, real-world, live data from diverse sources and integrated, standardized applications. They get the information they need with the business context they need to respond quickly. This provides significant efficiency gains and reduces errors caused by poor quality or inaccessible information and disjointed processes.
"Second, our front-line people often intuitively know what needs to be done to improve performance, but lack the tools to test their intuition. Controlled access to a rich universe of well-curated information turns our front-liners into 'citizen data scientists' who can own their reports and analyses, make better decisions, and demonstrate the viability of improvement possibilities with real data. After implementation, we can measure the actual effects of improvements. Doing all of this in a global platform across many sites allows us to rapidly spread this knowledge and multiply the gains. 'Continuous Improvement' really becomes continuous.
"Third, you don't know what you don't know. A unique value of Cognite Data Fusion's AI-powered data contextualization is how it provides us with the 'smarts’ to answer very complex questions and create visibility into new areas to explore."
"On behalf of Cognite, we are proud to partner with B. Braun as they transform into a data-first organization based on a strong operational data foundation. Cognite Data Fusion®, which provides simple access to complex industrial data, will fast track time to value of the Manufacturing Data Management solution and empower B. Braun to build and scale valuable business solutions," said Petteri Vainikka, Chief Marketing Officer at Cognite.
As part of the partnership, Cognite will collaborate with B. Braun to integrate its in-house support tools with Cognite’s user community, Cognite Hub, to provide seamless support to the B. Braun organization. To learn more about Cognite Data Fusion, visit: cognite.com/en/product/cognite_data_fusion_industrial_dataops_platform
About B. Braun
As one of the world's leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care, and patient benefits.
More than 66,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services, and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2021, the B. Braun Group generated sales of € 7.9 billion. Visit us at www.bbraun.com.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with open, contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005369/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
